Genomic Center - Projects
- Details
- Hits: 8152
Projects
INTERNATIONAL PROJECTS
H2020-MSCA-RISE-2018- nr 824036- Excellence in research and development of non-coding RNA DIAGnostics in Oncology - RNADIAGON
Period 2018-2023
H2020-MSCA-RISE-2019- Grant Agreement no.: 872391 – “Development of Cancer
RNA Therapeutics CONCRETE
Period 2019-2024
D-CARE 656/2020 - Developing, piloting and validating smart care models in Danube region for supporting social innovation, improving competences and entrepreneurship
Period 2020-2022
NATIONAL PROJECTS
PN-III-P4-ID-PCE-2020-1625 Testing small molecule targeting mitogen activated protein kinases: Successes, challenges and opportunities in triple negative breast cancer systems
Period 2021-2024
PN-III-P4-ID-PCE2020-1756 Low-moderate drinking water arsenic contamination, cigarette smoke and adverse pregnancy outcomes in timis county
Period 2021-2024
PN-III-P4-ID-PCE2020-2486 Modulation of the trained immunity by vaccination amplifiers MOTIVA
Period 2021-2024
PN-III-P1-1.2-PCCDI-2017-0737 ctr. 35 PCCDI Genomic population mapping of radioactive and heavy metals in order to increase national security - ARTEMIS
Period 2017 – 2021
POC-P_37_796 /2016 ctr 35/01.09.2016 Clinical and economic impact of personalized targeted therapies with anti - microARN in reconverting resistance of malignant lung tumors - CANTEMIR
Period: 2016-2021
POCU/380/6/13 - cod 125171 Academy of Researchers Entrepreneurs in Medicine
Period: 2019-2021
POC/398/1/1 - ID 125371 – Increasing the research capacity of UMF Iuliu Hațieganu Cluj Napoca, by developing a CLOUD type infrastructure connected to global information resources - CYRUS,
Period 2020-2021
PN-III-P2-2.1-PED-2019-2536 - ctr. 557PED/2020 Development of an intelligent combined imagistic - cytologic – molecular system to guide the diagnosis, risk stratification and the management of thyroid cancer (acronym - TIRCITOGEN)
Period 2020-2022
COMPLETED PROJECTS
International Projects
H2020-WIDESPREAD-2016-2017 ID 763560
Teaming Phase1 Romanian Centre of Excellence for Systems Immunology - ROCSI
Period: 2017-2018
PN-III-P3-3.1-PM-RO-CN-2018-0083 (Bilateral Cooperation Romania-China)
Experimental immunotherapy for haematological malignancie
Period 2018-2019
PN-III-P1-1.1-BT-2016-0021 SEE-027 - 1 / 25.06.2015
Innovative Nanoparticles-based Chemotherapy for Acute Myeloid Leukemia
Period: 2015-2016
PN-II-CT-RO-ZA-2014 – 1 ctr 7 BM/2016 (Bilateral Funding Romania- South Africa)
Use of new nanogold materials as delivery systems for modulation of MCL-1/p53 siRNA in ALL - NanoLAL
Period: 2016 – 2017
American International School of Bucharest (TERRY FOX) ctr.1110/23.07.2015
MicroRNAs biomarkers of response to chemotherapy and overall survival in colon cancer
Period: 2015-2016
57 BM/2016 Bilateral Funding (Beijing)
Non-invasive biomarkers for graft versus host disease following bone marrow hematopoietic stem cell transplantation
Period 2016-2017
NATIONAL RESEARCH PROJECTS
24SOL / 20.07.2020 Emergency development of molecular instruments for emergency and re-emergence assessment COVID-19
Period 2020
PNCDI III 2015-2020 - Ctr. nr. 29PFE/18.10.2018
Increasing the performance of scientific research and technology transfer in translational medicine through the formation of a new generation of young researchers - ECHITAS
Period 2018-2020
PN-III-P4-ID-PCE-2016-0795
Addressing the complex exposome profile in hormone-dependent cancers of the breast and prostate and its influence on tumoral genome – ACHILLE
Period: 2017-2019
CNFIS-FDI - CNFIS-FDI-2019-0666
Sustenance and valorification of research of excellence in the domain of personalized medicine by internationalization and increasement of research activities visibility
Period may 2019 – december 2019
PN-III-P1-1.1-TE-2016-2213
Targeting breast cancer resistance mechanism with combinatorial drug therapy using small molecules and siRNA, in post genomic era- DRUG_STORE
Period: 2018-2020
PN-III-P1-1.1-MCT-2018-0006
Mobility Projects for Young Researchers from the Diaspora. Professor Guest: Dr. Gabriel Ghiaur
Period 2018
PN-III-P1-1.1-MC-2018-0195 MC
Mobility Projects for Researchers Ciprian Tomuleasa
Period 2018
FDI-2018-0262
Correlation of the educational offer in molecular medicine and translational onco-hematology with the demand on the labor market at European level
Period 2018
CNFIS-FDI-2017-1350
Modern training for healthcare professionals affiliated to the departments of hematology, oncology and bone marrow transplantation
Period 2017
FSS PROJECT
FSS Project to implement activities to identify and promote innovative student-initiated ideas, business ideas, entrepreneurship and student start-ups 2017
Period 2017
PN-II-RU-TE-2014-4-1783
Massively parallel high-throughput DNA sequencing for the identification of microRNAs differentially expressed between the metastatic site and the tissue of origin in cancers of unknown primary site
Period: 2015-2017
PN-II-RU-TE-2014-4-1464 ctr.307/2015
TGF β signaling pathway tapering: an alternative to TGFtarget breast cancer therapy
Period: 2015-2017
PN-III-P1-1.1-MCD-2016-0049 MCD
Mobility projects for researchers with experience from diaspora (Prof.Dr. George Adrian Calin)
Period 2016
PN-II-PT-PCCA-2013-4-2289 Ctr. 137/2014
Developing a method for real-time detection and isolation of circulating tumor cells from the bloodstream of cancer patients by means of image processing and pattern recognition - CTC VideoScop
Period: 2014- 2017
F-SEE Romania – European Economic Space (EES) cod F-SEE-003/07.2013
Nanotechnology approach in Acute Myeloid Leukemia management” – NanoLAM. 1 / 16.01.2014,
Period 2014-2016
PN-II-PT-PCCA-2013-4-2166 ctr. 128/2014
New strategies for improving cancer patient’s quality of life and survival: molecular and clinical studies of cancer genome using depleted deuterium water model- GenCanD”
Period: 2014 - 2017
PN-II-PT-PCCA-2013-4-0030 ctr.196/2014
Modulation of pro/anticarcinogenic effect of toxic chemical agents in breast cancer multitargeted therapy - CANCERTER-p53
Period: 2014- 2017
PN-II-PT-PCCA-2013-4-1959 ctr.193/2014 Non-Invasive Intelligent Systems for Colorectal Cancer Diagnosis and Prognosis Based on Circulating miRNA Integrated in the Clinical Workflow – INTELCOR
Period: 2014-2017
ESR-14-10102/17.10.2014 ASTRA ZENECA Ctr.ESR-14-10102/17.10.2014
BRCA1 and BRCA2 mutation analysis in Romanian population: a study of genotype-phenotype correlation at diagnosis with prospective disease outcome and survival”.
Period: 2014-2016
PN-II-PT-PCCA-2011-3.1-1221 Ctr. 125/2012
Inteligent Systems of prediction of recurrence and progression in superficial bladder cancer based on artificial intelligence and microarray data: tumor mRNA and plasmatic microRNA - IntelUro
Period: 2012 - 2016
PN-II-PT-PCCA-2011-3.2-1328 Ctr. 96/2012
Analysis of microRNA biomarkers as predictive values for cervical cancer treatment, in relationship with environmental exposure to arsenic, phthalates and ETS - CERVICALL-ARSEN-ARRAY
Period: 2012 - 2016
POSCEE 2010 nr. 709/12683 ctr. 228/06.08.2010
Clinical and Economical Impact of the transcriptomic and proteomic molecular profile identification in the neoadjuvant therapy of triple negative breast cancer”-BREASTIMPACT
Period: 2010- 2014
FELLOWSHIP
Fellowship of the young researcher
Osan Ciprian-Ioan
Period 2017-2018
Program L’Oréal - UNESCO FOR WOMEN IN SCIENCE, Life Sciences Section- 4th edition (2012 - 2013), with a project entitled “Combining the chemotherapeutic effect of doxorubicin with RNA interference targeted therapy in the treatment of triple negative breast cancer” Cornelia Braicu
Period:2013-2014
INTERNAL GRANTS
Identifying a methylation profile of cancer-associated genes in squamous cell carcinoma
Period: 2016-2018
MicroRNA analysis in breast cancer late apoptotic mechanisms Pileczki Valentina -
Period 2014-2015
Cell and molecular mechanisms of primary myelofibrosis Tomuleasa Ciprian
Period 2014-2015
Circulating miRNAs as biomarkers for metastatic colorectal cancer - Petric Roxana
Period 2014-2015
INTERNAL GRANTS FOR STUDENTS
Target therapy in triple-negative breast cancer: evaluation of DNMT3b inhibition with nanaomycin A (students)
Period:2016-2018
A syntetic lethalaty approach in the acute myeloid leukaemia chemotherapy : PARP inhibitors plus anthreacycline plus decitabine vs anthreacycline plus decitabine – in vitro efficacy testing(students)
Period: 2016-2018
The efficacy of pirfenidone in the treatment of primary myelofibrosis (students)
Period: 2016-2018